E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Congenital heart disease ranks still within the top causes of infant mortality in industrialized countries. Despite considerable advances over the past decade, the exposure to cardiopulmonary bypass (CPB), which is needed for most heart surgeries, remains responsible for major side effects: The exposure of patient blood to large artificial surfaces in the CPB circuit triggers a very strong systemic inflammatory syndrome, which leads in a third of patients to low cardiac output syndrome (LCOS). |
|
E.1.1.1 | Medical condition in easily understood language |
Cardiac surgery often requires cardiopulmonary bypass. Children often develop an inflammatory response to bypass and this contributes to complications after surgery and delayed recovery. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate in a double blind randomized controlled trial in children undergoing open heart surgery if NO exposure during CPB reduces the postoperative duration of invasive mechanical ventilation (defined as ventilator free days within 28 days post randomisation) compared to control. |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate if NO reduces the incidence of low cardiac output syndrome (LCOS), requirement for extracorporeal life support (ECLS), and 90-day mortality.
2. To investigate if NO reduces the length of PICU stay and health care costs
3. To investigate if NO reduces the inflammatory response following CPB.
4. To investigate if NO reduces the ischaemic cerebral damage following congenital heart surgery with CPB.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Platelet function during cardiopulmonary bypass during surgery for congenital heart defects. To investigate if NO reduces the negative effects of CPB on platelet activation and platelet function. (This question is answered within the subgroup of children included at the Utrecht study side)
|
|
E.3 | Principal inclusion criteria |
- All infants and children < 2 years of age undergoing open heart surgery on CPB
- Elective cardiac surgery and consent of parents/guardian.
|
|
E.4 | Principal exclusion criteria |
- Signs of persistently elevated pulmonary vascular resistance preoperatively requiring iNO or preoperative use of intravenous drugs involved in the NO pathway such as GTN, within 48 hours prior to CPB.
- Patient is on ECLS prior to surgery
- Concurrent known confirmed bacterial sepsis/septic shock, diagnosed within <48 hours prior to surgery and being actively treated with antibiotics at time of surgery (suspected sepsis treated with antibiotics is not an exclusion criteria unless inotropes are required for
treatment of septic shock at time of surgery)
- Preoperative acute respiratory distress syndrome requiring HFOV ventilation <48 hours of surgery
- Patient requires high doses of vasoactive drugs prior to surgery with an inotrope score ≥15 met within 24 hours prior to surgery: Inotrope requirement will be calculated by means of the Vasoactive-Inotrope Score (VIS) (2): VIS = dopamine dose (mcg/kg/min) + dobutamine
dose (mcg/kg/min) + 100 x adrenaline dose (mcg/kg/min) + 100 x noradrenaline dose (mcg/kg/min) + 10 x milrinone dose (mcg/kg/min) + 10,000 x vasopressin dose (U/kg/min).
- Cardiac arrest within one week (7d) prior to surgery
- Emergency cardiac surgery which may preclude obtaining informed consent (defined as acutely required life-saving procedure in a patient unlikely to survive the next hours without the surgery)
- Pre-existing methaemoglobinemia (MetHb>3%)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Length of mechanical ventilation as defined as the duration of respiratory support for all episodes with an endotracheal tube in situ for the first 28 days post randomisation. The outcome will be reported using ventilator free days (VFD). A systematically zero value will be assigned for patient who die to allow important weight to death as the most pejorative outcome. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
28 days postsurgical intervention |
|
E.5.2 | Secondary end point(s) |
1- Incidence of LCOS, need for ECLS, and Mortality
2- The length of stay in PICU, hospital length of stay and health care costs
3- Levels of systemic inflammatory markers and levels of markers of myocardial injury
4- Platelet function and levels of markers for platelet activation prior, during, and after CPB
5- Extent of new and worsened ischemic white matter changes on cerebral MRI.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1- 28 days
2- 1 year postsurgical intervention
3- at 0,12, and 24 hours post surgery
4- day of surgery
5- during hospitalisation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
routine care, standard respiratory gases (oxygen-air mix) during bypass at a flow rate of 3L/min |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
1 year after completion of the last patient included/operated or when the DSMB may recommend ceasing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |